In pancreatic cancer, ANXA8 overexpression was also associated with higher histological grades and a lower survival in I-II stage patients, thereby emerging as a poor prognosis biomarker for early stages of pancreatic cancer (Pimiento et al., 2015). Here, ANXA8 is linked to familial pancreatic carcinoma.